OmniAb, Inc. reported a net loss of $16.5 million for the third quarter of 2025, translating to earnings of $0.14 per share—exactly in line with the consensus estimate of –$0.14. Revenue fell to $2.2 million, a 47.6% decline from $4.2 million in Q3 2024, and missed the consensus estimate of $5.64 million by 62.97%. The shortfall was driven by lower milestone revenue and a drop in service revenue tied to the completion of work on certain small‑molecule ion‑channel programs.
The company’s guidance for 2025 was revised downward: revenue is now expected to range between $18 million and $22 million, compared with the prior $20 million to $25 million range. Operating expenses are projected at $82 million to $86 million, a slight tightening from the previous $84 million to $88 million estimate. Management explained that the adjustment reflects a more cautious outlook on near‑term revenue generation while maintaining confidence in the long‑term growth of its platform.
OmniAb’s cash position strengthened after a $30 million private placement completed in August 2025, leaving the company with $59.5 million in cash, cash equivalents, and short‑term investments. The infusion provides a runway to continue investing in research and development and to support the launch of new technologies such as OmniUltra, which is slated for release next month.
CEO Matt Foehr highlighted continued program momentum, noting that the number of new program additions this year has significantly outpaced last year, bolstering the partnered pipeline. He also emphasized the company’s focus on expanding the Exploration Partner Access Program and other platform offerings to generate new revenue streams, while announcing the upcoming launch of OmniUltra as a key driver of future growth.
Market reaction to the earnings was positive, with the stock rising 2.36% in aftermarket trading. Investors appeared to weigh the company’s strategic initiatives, strengthened balance sheet, and EPS meeting expectations more heavily than the revenue miss, indicating confidence in OmniAb’s long‑term potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.